Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Inclusion criteria * Medical diagnosis of CTCL, and positivity for the CD4 receptor. * Early stage CTCL * Have received at least two prior therapies with inadequate effect, including phototherapy and/or electron beam, and/or chemotherapy. * Histopathological evidence of large cell transformation or poorly differentiated tumors or prior treatment with anti-CD4 monoclonal antibodies excluded participants from inclusion in the study. Exclusion Criteria * Certain rare types of CTCL. * Previous treatment with other anti-CD4 medications. * More than two previous treatments with systemic chemotherapy. * Certain anti-psoriasis or anti-cancer therapies within the last 4 weeks before entering this trial. * Some types of steroid treatments less than two weeks before entering the trial. * Prolonged exposure to sunlight or UV light during the trial. * Other cancer diseases, except certain skin cancers or cervix cancer. * Chronic infectious disease requiring medication. * Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, lung, heart, hormonal, nerve or blood diseases. * Pregnant or breast-feeding women. * Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial. * If you are participating in another trial with a different new drug 4 weeks before you enter this trial. Note: Other protocol defined Inclusion and Exclusion criteria may apply.